BioCentury
ARTICLE | Emerging Company Profile

Tempo: Two-in-one approach

May 28, 2007 7:00 AM UTC

Differences in dosing schedules between angiogenesis inhibitors and chemotherapeutics and the fact that anti-angiogenics reduce the vasculature that delivers chemo to tumors can make optimizing the combination difficult. Tempo Pharmaceuticals Inc. believes its Nanocell drug delivery system can improve the therapeutic index of the combination by enabling timed release of two drugs within diseased tissue.

The company raised $12.1 million in a series A round last week to test Nanocell in the clinic...